Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyle Crassini

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Ejhaem|July 18, 2022
The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLLNarjis Fatima, Yandong Shen, Kyle Crassini, et al.
Internal Medicine Journal|July 27, 2025
Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitorsMary Ann Anderson, Farrukh T Awan, Leanne Berkahn, et al.
Leukemia & Lymphoma|January 16, 2024
The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells <i>in vitro</i>Narjis Fatima, Yandong Shen, Kyle Crassini, et al.
Internal Medicine Journal|September 24, 2023
Chronic lymphocytic leukaemia Australasian consensus practice statementMary A Anderson, Rory Bennett, Xavier Badoux, et al.
Internal Medicine Journal|July 7, 2026
Australasian chronic lymphocytic leukaemia consensus statement: 2026 updateSean McKeague, Joanna Katarzyna Czerwinski, Xavier Badoux, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Ejhaem|July 18, 2022
The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLLNarjis Fatima, Yandong Shen, Kyle Crassini, et al.
Internal Medicine Journal|July 27, 2025
Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitorsMary Ann Anderson, Farrukh T Awan, Leanne Berkahn, et al.
Leukemia & Lymphoma|January 16, 2024
The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells <i>in vitro</i>Narjis Fatima, Yandong Shen, Kyle Crassini, et al.
Internal Medicine Journal|September 24, 2023
Chronic lymphocytic leukaemia Australasian consensus practice statementMary A Anderson, Rory Bennett, Xavier Badoux, et al.
Internal Medicine Journal|July 7, 2026
Australasian chronic lymphocytic leukaemia consensus statement: 2026 updateSean McKeague, Joanna Katarzyna Czerwinski, Xavier Badoux, et al.
Pageof 2